Alopecia areata during etanercept therapy

Area of Science:

• Rheumatology
• Dermatology
• Immunology

Background:

• Anti-tumor necrosis factor (TNF) agents are widely used to treat autoimmune diseases like ankylosing spondylitis.
• These therapies are designed to modulate the immune system and are generally expected to reduce autoimmune processes.

Observation:

• A case report details a 44-year-old male patient with ankylosing spondylitis undergoing treatment with etanercept, a TNF inhibitor.
• The patient experienced approximately six months of progressive, patchy hair loss.

Findings:

• The observed hair loss was clinically consistent with alopecia areata.
• The development of alopecia areata occurred during the course of anti-TNF therapy with etanercept.

Implications:

• This case suggests a potential causal relationship between anti-TNF agents and the development of alopecia areata, contrary to expectations.
• Ophthalmologists and other clinicians utilizing these biologic agents should be vigilant for and counsel patients on potential dermatological side effects, including hair loss.